Please wait while we load the requested 10-K report or click the link below:
RBC Reports Record 2007 Earnings
Halliburton Investor Relations, 972-458-8000
Geralyn DeBusk, firstname.lastname@example.org
Chase Zavoina, email@example.com
Jeff Elliott, firstname.lastname@example.org
Irving, Texas (March 6, 2008) –RBC Life Sciences, Inc. (OTCBB: RBCL) today announced that net sales for the year-ended December 31, 2007 increased 25 percent to $27.0 million, compared to net sales of $21.7 million for the year-ended December 31, 2006. The Company’s net earnings for 2007 improved more than 280 percent to $1.7 million, or $0.08 per diluted share, compared to net earnings of $436,000, or $0.02 per diluted share in 2006.
“The significant increase in net sales and earnings this year is a direct result of the exceptional sales growth in both our nutritional supplements and our medical products segments, in addition to an overall improvement in our operating profit margin,” stated Clinton Howard, Chairman and CEO. “The noteworthy growth of our international nutritional supplement sales under license agreements was particularly strong. We look forward to further developing our international business throughout 2008 as we see that as a strong growth driver for the company. Additionally, comparative earnings for 2006 were lower due to expenses associated with an office in Asia that was sold in October 2006.”
RBC Life Sciences develops, manufactures and markets skin care products and food supplements providing nutrients often found to be low or missing in modern diets. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed.
MPM Medical, a wholly owned subsidiary of RBC, develops and markets proprietary prescription and nonprescription products for wound and pain management, sold through medical-surgical dealers to nursing homes, hospitals and cancer clinics.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including but not limited to changes in plans by the Company’s management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company’s filings with the Securities and Exchange Commission.
The following information was filed by Rbc Life Sciences, Inc. (RBCL) on Friday, March 7, 2008 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Rbc Life Sciences, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Rbc Life Sciences, Inc..